<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02694458</url>
  </required_header>
  <id_info>
    <org_study_id>2015-A01545-44</org_study_id>
    <nct_id>NCT02694458</nct_id>
  </id_info>
  <brief_title>Comparison of Two Dosage Adjustment Strategies of Vancomycin in Children</brief_title>
  <acronym>OPTIBAYE</acronym>
  <official_title>Comparison of Two Dosage Adjustment Strategies of Vancomycin in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vancomycin is the standard first-line treatment for MRSA infections and a first-line empiric&#xD;
      therapy. The relationship between exposure to vancomycin and efficacy is admitted but because&#xD;
      of an important intersubject variability, therapeutic exposure isn't usually achieved.&#xD;
&#xD;
      The primary aim of this randomized controlled trial is to evaluate a new early dosage&#xD;
      adjustment strategy of vancomycin in children, comparing it to the usual treatment strategy.&#xD;
&#xD;
      Using a bayesian approach, the purpose is to achieve earlier a therapeutic and non-toxic&#xD;
      exposure to vancomycin.&#xD;
&#xD;
      The primary hypothesis is that an early dosage adjustment strategy using a bayesian approach&#xD;
      will allow patients to achieve the vancomycin pharmacological target faster than with the&#xD;
      usual treatment strategy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Introduction/ Clinical significance :&#xD;
&#xD;
      Staphylococcus aureus is a common cause of serious infections. Methicillin-resistant&#xD;
      Staphylococcus aureus (MRSA) are one of the most common causes of nosocomial antibiotic&#xD;
      resistant bacterial infections in the world. According to the last data from the European&#xD;
      Antimicrobial Resistance Network, in 2014, 17,4 % of invasive staphylococcal infections are&#xD;
      due to MRSA in France, with proportions of up to 56 % in some regions in the European&#xD;
      Economic Area (EEA). In the United-States of America, MRSA reach 50 % of Staphylococcus&#xD;
      isolates in some studies. Vancomycin is the standard first-line treatment for MRSA infections&#xD;
      and a first-line empiric therapy.&#xD;
&#xD;
      To optimize good clinical outcomes for invasive MRSA infections using&#xD;
      pharmacokinetics-pharmacodynamics of vancomycin, studies support targeting area under the&#xD;
      curve (AUC) of the serum concentration versus time over 24 hours to minimum inhibitory&#xD;
      concentration (MIC) ratio ≥ 400, which frequently correlates to a trough concentration of 15&#xD;
      - 20 mg/L when the MIC is 1 mg/L. Because of few consensus regarding the dosage to use and&#xD;
      high intersubject variability, this pharmacological target is difficult to reach in children,&#xD;
      which may lead to a delayed infection control and an increase of vancomycin toxicity-related&#xD;
      side effects.&#xD;
&#xD;
      Aims :&#xD;
&#xD;
      The primary aim is to evaluate an early dosage adjustment strategy of vancomycin in children,&#xD;
      comparing it to the usual treatment strategy.&#xD;
&#xD;
      Using a bayesian approach, the main purpose is to achieve earlier a therapeutic and non-toxic&#xD;
      exposure to vancomycin.&#xD;
&#xD;
      The secondary aims are to compare with the usual treatment strategy 1) the proportion of&#xD;
      subjects with vancomycin serum concentration within the concentration targets at the 24th&#xD;
      hour of treatment, and 2) the clinical (in terms of fever), biological (in terms of CRP) and&#xD;
      bacteriological (in terms of blood culture) efficacy of this early dosage adjustment strategy&#xD;
      of vancomycin.&#xD;
&#xD;
      Hypothesis :&#xD;
&#xD;
      This study hypothesizes that early dosage adjustment strategy of vancomycin using a bayesian&#xD;
      approach will be superior to usual treatment strategy in achieving the pharmacological target&#xD;
      of vancomycin at the 24th hour of treatment in children.&#xD;
&#xD;
      Methodology :&#xD;
&#xD;
      As part of routine care, a prospective open-label randomized controlled trial will be&#xD;
      conducted in a major paediatric hospital in Paris, France. Subjects will be divided into two&#xD;
      arms. Each arm will contain 50 subjects.&#xD;
&#xD;
      For subjects of the Modeling arm, drug concentration will be measured at the 3rd hour of&#xD;
      treatment and dosage adjustment will be done at the 6th hour of treatment using a bayesian&#xD;
      approach. Vancomycin serum concentration will be then measured at the 24th hour of treatment.&#xD;
&#xD;
      Subjects of the control arm will receive the usual treatment strategy. Vancomycin serum&#xD;
      concentration will be measured at the 24th hour of treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 23, 2016</start_date>
  <completion_date type="Actual">February 15, 2017</completion_date>
  <primary_completion_date type="Actual">February 15, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects with vancomycin AUC/MIC ≥ 400 and serum trough concentration ≤ 20 mg/L</measure>
    <time_frame>24th hour of treatment</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Methicillin-resistant Staphylococcal Infections</condition>
  <arm_group>
    <arm_group_label>Modeling arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Early vancomycin monitoring and bayesian dosage adjustment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Usual vancomycin dose and monitoring strategy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Early vancomycin monitoring and bayesian dosage adjustment</intervention_name>
    <description>Measure of vancomycin serum concentration at the 3rd hour of treatment and adjustment of vancomycin dosage at the 6th hour of treatment using a bayesian approach. Then measure of vancomycin serum concentration at the 24th hour of treatment.</description>
    <arm_group_label>Modeling arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>usual vancomycin dose and monitoring strategy</intervention_name>
    <description>Vancomycin serum concentration will be measured at the 24th hour of treatment.</description>
    <arm_group_label>Control arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Children aged 1 months to 16 years&#xD;
&#xD;
          -  Children for whom a vancomycin treatment is started in the hospital Necker-Enfants&#xD;
             Malades in Paris, France&#xD;
&#xD;
          -  No objection of parents and of the child himself if he is able to express it.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients undergoing hemodialysis&#xD;
&#xD;
          -  Patients undergoing peritoneal dialysis&#xD;
&#xD;
          -  Newborns less than 1 months old&#xD;
&#xD;
          -  Adolescents more than 16 years old and adults&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Marc TRELUYER, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Necker-Enfants Malades</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Necker-Enfants Malades</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Le J, Bradley JS, Murray W, Romanowski GL, Tran TT, Nguyen N, Cho S, Natale S, Bui I, Tran TM, Capparelli EV. Improved vancomycin dosing in children using area under the curve exposure. Pediatr Infect Dis J. 2013 Apr;32(4):e155-63. doi: 10.1097/INF.0b013e318286378e.</citation>
    <PMID>23340565</PMID>
  </reference>
  <reference>
    <citation>Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, J Rybak M, Talan DA, Chambers HF; Infectious Diseases Society of America. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011 Feb 1;52(3):e18-55. doi: 10.1093/cid/ciq146. Epub 2011 Jan 4. Erratum in: Clin Infect Dis. 2011 Aug 1;53(3):319.</citation>
    <PMID>21208910</PMID>
  </reference>
  <reference>
    <citation>Hoang J, Dersch-Mills D, Bresee L, Kraft T, Vanderkooi OG. Achieving therapeutic vancomycin levels in pediatric patients. Can J Hosp Pharm. 2014 Nov;67(6):416-22.</citation>
    <PMID>25548398</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>February 24, 2016</study_first_submitted>
  <study_first_submitted_qc>February 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 29, 2016</study_first_posted>
  <last_update_submitted>April 2, 2021</last_update_submitted>
  <last_update_submitted_qc>April 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vancomycin</keyword>
  <keyword>Children</keyword>
  <keyword>Infection</keyword>
  <keyword>Antibiotic</keyword>
  <keyword>Methicillin-resistant Staphylococcus aureus (MRSA)</keyword>
  <keyword>Population-based pharmacokinetic modeling</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Bayesian approach</keyword>
  <keyword>Therapeutic drug monitoring</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Staphylococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

